Back to top
more

Amedisys (AMED)

(Real Time Quote from BATS)

$91.49 USD

91.49
278,954

+0.14 (0.15%)

Updated Apr 16, 2024 03:00 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.15%
2Buy18.00%
3Hold9.44%
4Sell5.10%
5Strong Sell2.53%
S&P50011.08%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

C Value B Growth C Momentum B VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 37% (93 out of 251)

Industry: Medical - Outpatient and Home Healthcare

Better trading starts here.

Zacks News

Why Amedisys (AMED) is a Top Value Stock for the Long-Term

Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.

Why Is Amedisys (AMED) Down 2.5% Since Last Earnings Report?

Amedisys (AMED) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

How Amedisys (AMED) Stock Stands Out in a Strong Industry

Amedisys (AMED) has seen solid earnings estimate revision activity over the past month, and belongs to a strong industry as well.

Why This 1 Momentum Stock Could Be a Great Addition to Your Portfolio

Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.

Are You a Value Investor? This 1 Stock Could Be the Perfect Pick

The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.

Amedisys' (AMED) Q4 Earnings Miss Estimates, Margins Up

The continuous shortage of clinical labor, nursing in particular, is likely to have impacted Amedisys' (AMED) Q4 performance.

AMED vs. USPH: Which Stock Is the Better Value Option?

AMED vs. USPH: Which Stock Is the Better Value Option?

Amedisys (AMED) Reports Q4 Earnings: What Key Metrics Have to Say

While the top- and bottom-line numbers for Amedisys (AMED) give a sense of how the business performed in the quarter ended December 2023, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.

Amedisys (AMED) Q4 Earnings Lag Estimates

Amedisys (AMED) delivered earnings and revenue surprises of -9.62% and 1.05%, respectively, for the quarter ended December 2023. Do the numbers hold clues to what lies ahead for the stock?

Higher Visits to Soften Cost Blow for Teladoc (TDOC) Q4 Earnings

Teladoc's (TDOC) fourth-quarter results are likely to reflect growth in BetterHelp's profit levels.

Can Low Patient Days Affect Community Health (CYH) Q4 Earnings?

Community Health's (CYH) fourth-quarter results are likely to reflect lower adjusted admissions, declining beds in services and occupancy rate.

Centene (CNC) to Provide Better Health Equity in North Carolina

Centene (CNC) collaborates with Reinvestment Partners to improve the health of North Carolinians.

Amedisys (AMED) Expected to Beat Earnings Estimates: What to Know Ahead of Q4 Release

Amedisys (AMED) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Philips (PHG) Q4 Earnings Beat Estimates, Revenues Fall Y/Y

Philips' (PHG) fourth-quarter results benefit from strong momentum across the Diagnosis & Treatment and Personal Health businesses. However, softness in the Connected Care business is a concern.

Chemed (CHE) Up 4.8% Since Last Earnings Report: Can It Continue?

Chemed (CHE) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Amedisys (AMED) Up 2.6% Since Last Earnings Report: Can It Continue?

Amedisys (AMED) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Amedisys' (AMED) Q3 Earnings Miss Estimates, Margins Up

The continuous shortage of clinical labor, nursing in particular, is likely to have impacted Amedisys' (AMED) Q3 performance.

Amedisys (AMED) Reports Q3 Earnings: What Key Metrics Have to Say

Although the revenue and EPS for Amedisys (AMED) give a sense of how its business performed in the quarter ended September 2023, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.

Amedisys (AMED) Q3 Earnings and Revenues Lag Estimates

Amedisys (AMED) delivered earnings and revenue surprises of -9.26% and 0.99%, respectively, for the quarter ended September 2023. Do the numbers hold clues to what lies ahead for the stock?

Henry Schein (HSIC) Acquires Majority Stake in Shield Healthcare

Henry Schein (HSIC) completes the majority investment in Shield Healthcare, Inc.

Is Amedisys (AMED) Stock Outpacing Its Medical Peers This Year?

Here is how Amedisys (AMED) and Cybin Inc. (CYBN) have performed compared to their sector so far this year.

Philips (PHG) Aids Clinicians With New Monitoring Solution

Philips (PHG) launches Visual Patient Avatar to help anesthesiologists with situational awareness in operating rooms, boosting their clinical confidence.

Are Medical Stocks Lagging Clover Health Investments (CLOV) This Year?

Here is how Clover Health Investments, Corp. (CLOV) and Amedisys (AMED) have performed compared to their sector so far this year.

Encompass Health (EHC) Up 2.9% Since Last Earnings Report: Can It Continue?

Encompass Health (EHC) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Amedisys (AMED) Q2 Earnings Beat Estimates, Margins Dip

Strength in Hugh Acuity Care segment and Hospice division drive Amedisys (AMED) Q2 performance.